To access the full text documents, please follow this link: http://hdl.handle.net/2445/130119
dc.contributor.author | Gómez Miragaya, Jorge |
---|---|
dc.contributor.author | Palafox Sánchez, Marta |
dc.contributor.author | Paré, Laia |
dc.contributor.author | Yoldi, Guillermo |
dc.contributor.author | Ferrer, Irene |
dc.contributor.author | Vila, Sergi |
dc.contributor.author | Galván, Patricia |
dc.contributor.author | Pellegrini, Pasquale |
dc.contributor.author | Pérez-Montoyo, Hector |
dc.contributor.author | Igea, Ana |
dc.contributor.author | Muñoz Moruno, Purificación |
dc.contributor.author | Esteller, Manel |
dc.contributor.author | Nebreda, Àngel R. |
dc.contributor.author | Urruticoechea Ribate, Ander |
dc.contributor.author | Morilla, Idoia |
dc.contributor.author | Pernas, Sònia |
dc.contributor.author | Climent, Fina |
dc.contributor.author | Soler, María Teresa |
dc.contributor.author | Petit, Anna |
dc.contributor.author | Serra, Violeta |
dc.contributor.author | Prat Aparicio, Aleix |
dc.contributor.author | González Suárez, Eva |
dc.date | 2019-03-12T11:56:23Z |
dc.date | 2019-03-12T11:56:23Z |
dc.date | 2017-05 |
dc.date | 2019-03-12T11:56:23Z |
dc.identifier.citation | 2213-6711 |
dc.identifier.citation | 673483 |
dc.identifier.uri | http://hdl.handle.net/2445/130119 |
dc.format | 16 p. |
dc.format | application/pdf |
dc.language.iso | eng |
dc.publisher | Elsevier |
dc.relation | Reproducció del document publicat a: https://doi.org/10.1016/j.stemcr.2017.03.026 |
dc.relation | Stem Cell Reports, 2017, vol. 8, num. 5, p. 1392-1407 |
dc.relation | https://doi.org/10.1016/j.stemcr.2017.03.026 |
dc.rights | cc-by (c) Gómez Miragaya, Jorge et al., 2017 |
dc.rights | info:eu-repo/semantics/openAccess |
dc.rights | http://creativecommons.org/licenses/by/3.0/es |
dc.subject | Medicaments antineoplàstics |
dc.subject | Ús terapèutic |
dc.subject | Resistència als medicaments |
dc.subject | Metabolisme |
dc.subject | Integrines |
dc.subject | Càncer de mama |
dc.subject | Antineoplastic agents |
dc.subject | Therapeutic use |
dc.subject | Drug resistance |
dc.subject | Metabolism |
dc.subject | Integrins |
dc.subject | Breast cancer |
dc.title | Resistance to taxanes in triple negative breast cancer associates with the dynamics of a CD49f+ tumor initiating population |
dc.type | info:eu-repo/semantics/article |
dc.type | info:eu-repo/semantics/publishedVersion |
dc.description.abstract |